繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

CureVac's Q2 Pre-Tax Loss Widens, Revenue Rises; Finance Chief Pierre Kemula to Depart

2024-08-15 20:24

08:24 AM EDT, 08/15/2024 (MT Newswires) -- CureVac (CVAC) reported a Q2 pre-tax loss Thursday of 71.2 million euros ($78.4 million), widening from a loss of 67.4 million euros a year earlier.

Revenue for the quarter ended June 30 was 14.4 million euros, up from 7.6 million euros a year earlier.

Analysts' estimates were not immediately available for comparison.

At the end of June, the company had 202.5 million euros in cash and cash equivalents. The company reaffirmed its expected cash runway into 2028.

The biotech company said that Chief Financial Officer Pierre Kemula will be departing at the end of his term on Oct. 31. CureVac has started a search for Kemula's successor.

Price: 3.3500, Change: +0.04, Percent Change: +1.21

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。